Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Electrical tumor treatment fields for non-small cell lung cancer

PMA Number: P230042 · 2026-07-01

ApplicantNovocure, GmbH
Decision Date2026-07-01
PMA NumberP230042
Product CodeSDA
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeAN

Device Summary

Electrical tumor treatment fields for non-small cell lung cancer is the device name listed in this FDA 510(k) record. The listed applicant is Novocure, GmbH. It received FDA 510(k) clearance on 2026-07-01. The device is classified under product code SDA. It was reviewed by the AN advisory panel.

Frequently Asked Questions

What is the Electrical tumor treatment fields for non-small cell lung cancer?

Electrical tumor treatment fields for non-small cell lung cancer is a medical device that received FDA 510(k) clearance on 2026-07-01. The listed applicant is Novocure, GmbH.

When did Electrical tumor treatment fields for non-small cell lung cancer receive FDA 510(k) clearance?

The clearance date for Electrical tumor treatment fields for non-small cell lung cancer can be found in the official FDA records.

Who is the listed applicant for Electrical tumor treatment fields for non-small cell lung cancer?

The FDA 510(k) record lists Novocure, GmbH as the applicant. This does not by itself establish the device manufacturer.

What is the FDA product code for Electrical tumor treatment fields for non-small cell lung cancer?

The FDA product code for Electrical tumor treatment fields for non-small cell lung cancer is SDA.

Related Clinical Trials

Related records are matched automatically using names, product codes, or other metadata. A match does not establish a verified clinical, scientific, corporate, or regulatory relationship; review the linked official sources.

NCT07608549FLASH Pilot Phase 1 Safety StudyNOT_YET_RECRUITINGNCT06562205PAP Systems External Clinical Studies (ECS)NOT_YET_RECRUITINGNCT04745156A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade GliomasNOT_YET_RECRUITINGNCT06443177The Effect of Sympathetic Modulation on Cerebral Vasospasm Secondary to Aneurysmal Subarachnoid HemorrhageSUSPENDED

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑